NMN IV Therapy (200mg)

Entry-level NMN intravenous infusion delivering 200mg of nicotinamide mononucleotide directly into the bloodstream, bypassing digestive absorption losses. NMN is a precursor to NAD+, a coenzyme involved in cellular energy production and DNA repair pathways that naturally decline with age. The 200mg dose is designed as an introductory session for patients new to NMN therapy.

Nicotinamide mononucleotide (NMN) is a naturally occurring molecule and a direct precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme present in every living cell that plays a central role in energy metabolism, DNA repair, and gene expression regulation. Research has shown that NAD+ levels decline significantly with age, and this decline is associated with many hallmarks of ageing including mitochondrial dysfunction, impaired DNA repair capacity, and reduced cellular energy output. The 200mg IV infusion at TGWAC delivers NMN directly into the bloodstream, achieving bioavailability that oral supplements cannot match due to gastrointestinal degradation and first-pass liver metabolism. This entry-level dose is suited to patients who are new to NMN therapy and want to gauge their individual response before progressing to higher concentrations. During the 45-minute session, the NMN solution is administered via a slow IV drip in a private treatment room. Patients typically remain seated comfortably throughout, and most report no significant side effects. The clinic recommends an initial course of three to four sessions spaced one to two weeks apart to establish a baseline response, after which maintenance frequency can be adjusted based on individual goals and physician assessment. Preclinical studies in animal models have demonstrated that NMN supplementation may support improvements in insulin sensitivity, cardiovascular function, and cognitive performance, though human clinical data remains in early stages. TGWAC physicians discuss realistic expectations during an initial consultation and may recommend combining NMN therapy with baseline NAD+ level testing to track changes over time.